TY - JOUR
T1 - Non-specific gastrointestinal features
T2 - Could it be Fabry disease?
AU - Hilz, Max J.
AU - Arbustini, Eloisa
AU - Dagna, Lorenzo
AU - Gasbarrini, Antonio
AU - Goizet, Cyril
AU - Lacombe, Didier
AU - Liguori, Rocco
AU - Manna, Raffaele
AU - Politei, Juan
AU - Spada, Marco
AU - Burlina, Alessandro
N1 - Funding Information:
A. Burlina has received speaker honoraria and travel support from Sanofi Genzyme, Amicus, Biomarin, and Nutricia; he is a member of the European Advisory Board of the Fabry Registry, which is sponsored by Sanofi Genzyme.
Funding Information:
The development of this publication and the Internal Medicine Advisory Board in Rare Diseases (10 December 2016, in Rome, Italy) were sponsored by Sanofi Genzyme . The authors received editorial/writing support in the preparation of this manuscript from Rosalie Gadiot, PhD, of Excerpta Medica, which was funded by Sanofi Genzyme. The authors were responsible for all content and editorial decisions and received no honoraria related to the development of this publication.
Publisher Copyright:
© 2018 The Authors
PY - 2018/5
Y1 - 2018/5
N2 - Non-specific gastrointestinal symptoms, including pain, diarrhoea, nausea, and vomiting, can be the first symptoms of Fabry disease. They may suggest more common disorders, e.g. irritable bowel syndrome or inflammatory bowel disease. The confounding clinical presentation and rarity of Fabry disease often cause long diagnostic delays and multiple misdiagnoses. Therefore, specialists involved in the clinical evaluation of non-specific upper and lower gastrointestinal symptoms should recognize Fabry disease as a possible cause of the symptoms, and should consider Fabry disease as a possible differential diagnosis. When symptoms or family history suggest Fabry disease, in men, low alpha-galactosidase A enzyme levels, and in women, specific Fabry mutations confirm the diagnosis. In addition to symptomatic treatments, disease-specific enzyme replacement therapy with recombinant human alpha-galactosidase A enzyme or chaperone therapy (migalastat) in patients with amenable mutations can improve the disease, including gastrointestinal symptoms, and should be initiated as early as possible after Fabry disease has been confirmed; starting enzyme replacement therapy at as young an age as possible after diagnosis improves long-term clinical outcomes. Improved diagnostic tools, such as a modified gastrointestinal symptom rating scale, may facilitate diagnosing Fabry disease in patients with gastrointestinal symptoms of unknown cause and thus assure timely initiation of disease-specific treatment.
AB - Non-specific gastrointestinal symptoms, including pain, diarrhoea, nausea, and vomiting, can be the first symptoms of Fabry disease. They may suggest more common disorders, e.g. irritable bowel syndrome or inflammatory bowel disease. The confounding clinical presentation and rarity of Fabry disease often cause long diagnostic delays and multiple misdiagnoses. Therefore, specialists involved in the clinical evaluation of non-specific upper and lower gastrointestinal symptoms should recognize Fabry disease as a possible cause of the symptoms, and should consider Fabry disease as a possible differential diagnosis. When symptoms or family history suggest Fabry disease, in men, low alpha-galactosidase A enzyme levels, and in women, specific Fabry mutations confirm the diagnosis. In addition to symptomatic treatments, disease-specific enzyme replacement therapy with recombinant human alpha-galactosidase A enzyme or chaperone therapy (migalastat) in patients with amenable mutations can improve the disease, including gastrointestinal symptoms, and should be initiated as early as possible after Fabry disease has been confirmed; starting enzyme replacement therapy at as young an age as possible after diagnosis improves long-term clinical outcomes. Improved diagnostic tools, such as a modified gastrointestinal symptom rating scale, may facilitate diagnosing Fabry disease in patients with gastrointestinal symptoms of unknown cause and thus assure timely initiation of disease-specific treatment.
KW - Abdominal pain
KW - Diarrhoea
KW - Enzyme replacement therapy
KW - Fabry disease
KW - Lysosomal storage disorders
KW - OMIM #301500
KW - Rare diseases
UR - http://www.scopus.com/inward/record.url?scp=85044612764&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2018.02.011
DO - 10.1016/j.dld.2018.02.011
M3 - Review article
C2 - 29602572
AN - SCOPUS:85044612764
SN - 1590-8658
VL - 50
SP - 429
EP - 437
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 5
ER -